Fulgent Genetics, Inc. (FLGT)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Bullish pullback-to-support: FLGT gapped +15.97% on 2026-11-06 and is consolidating above every major moving average on declining volume; buy limit 24.40 at the 2026-11-13 swing low 24.345, protective stop 23.09 (1.0×ATR pullback floor, also below the 23.32 base low), targets 27.02 / 28.99, R/R 2.00.
Company overview
Fulgent Genetics, Inc. provides a wide range of genetic and molecular diagnostic testing services globally, including oncology panels, carrier screening, and rapid whole genome testing. The company also offers COVID-19 diagnostic solutions and advanced laboratory analyses such as flow cytometry and immunohistochemistry. It serves a diverse clientele including healthcare providers, laboratories, and government agencies.
Fundamental
fairFulgent Genetics shows a strong balance sheet but faces operating challenges and legal uncertainties.
Fortress balance sheet, weak operating economics. Fulgent holds roughly $652 million of cash and marketable securities against a $689 million market capitalisation and only about $2 million of debt, but the laboratory business is still GAAP loss-making with gross margin compressing to 32% from 41%, a trailing operating loss that widened to about $127 million, and roughly $19.8 million of underlying cash burn over nine months of 2026 once the one-time $112.3 million investment-tax-credit refund is stripped out. Open DOJ False Claims Act demands and an HRSA audit covering $548.9 million of COVID-era Uninsured Program reimbursements carry an unquantified exposure larger than annual revenue, with no reserve recorded. Asset backing, an aggressive buyback and low-single-digit revenue growth offset the losses enough for a mixed rather than a broken picture, but risk is elevated and the $19 analyst consensus target sits below the current quote.
Sentiment
fairRecent earnings were rewarded by the market, but no new catalysts are imminent.
Dominant near-term driver is the Q3 2026 print (announced, 2026-11-05): a non-GAAP loss of $(0.09) per share against a $(0.65) consensus loss — a $0.56 beat — with revenue above estimates and FY2026 guidance reaffirmed, and the market demonstrably rewarded it with a 20.3% single-day gain, although eight days on the reward looks largely absorbed against Piper Sandler's freshly raised $25 target. The sentiment delta is indeterminate because the baseline window produced zero unique on-topic scored items (all five scored items were name collisions on other diagnostics companies), retail reads are unavailable behind a Reddit 403 access block, and the Red-Flag Screen is clean with no severe or moderate flag fired — so the rewarded-but-digested character of the beat, with no forward-dated driver inside the horizon, holds the setup in the forming/mixed-constructive band rather than an actionable-now one.
Technical
goodThe stock is consolidating above major moving averages after a significant earnings-driven gap.
Post-earnings-gap consolidation inside an intact uptrend. FLGT closed 2026-11-13 at 24.66 above sma20 21.66, sma50 21.38, sma200 19.13, ema9 23.74, ema21 22.42, wma9 24.35, wma21 22.50 and dema14 24.48, after a +15.97% gap on 2026-11-06 (close 23.74 on 1.10M shares) that extended to a 26.15 close / 26.66 high on 2026-11-09 (974K shares). The four-session fade to 24.66 came on contracting volume (494.6K → 287.4K → 262.1K) and held every low above the 2026-11-09 base low 23.32 — consolidation, not distribution. Momentum is constructive: RSI14 62.30 (cooled from 70.82 without breaking), Williams %R -30.66, MACD line 1.10 above signal 0.56 and both above zero, histogram +0.54, and ADX14 24.97 rising for eight straight sessions with price above the key MAs — trend strength improving with, not against, the price. ATR14 1.31 = 5.31% of price supplies tradable daily range. The one weak signal: price is 0.2% under the daily VWAP 24.72 and the MACD histogram has contracted three sessions running, so the push has lost some urgency. Scored 4.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

